Skip to main content
Fig. 7 | Journal for ImmunoTherapy of Cancer

Fig. 7

From: Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells

Fig. 7

POG enhances the antitumour effect of PD-1 inhibitor in mouse tumour models of B16-F10 and 4 T1. a-B) The tumour growth curves of 4 T1 tumour-bearing mice after POG and anti-PD-1 antibody (alone or in combination) treatment (n = 6). c-d The tumour growth curves of 4 T1 tumour-bearing mice after POG and anti-PD-1 antibody (alone or in combination) treatment (n = 6). e-f Survival rate of 4 T1 tumour-bearing mice with POG and anti-PD-1 antibody (alone or in combination) treatment (n = 6) g-h Survival rate of B16-F10 tumour-bearing mice with POG and anti-PD-1 antibody (alone or in combination) treatment (n = 6). The pooled data from three independent experiments are shown. All data are represented as the mean ± SD. * p < 0.05, ** p < 0.01, ***p < 0.001, ****p < 0.0001

Back to article page